- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01930032
Pathogenic Mechanisms in C Diff Infection and Colitis
Pathogenic Mechanisms in Clostridium Difficile Infection and Colitis
The purpose of this study is to learn more about infection by Clostridium difficile (also known as C. difficile). C. difficile is a common bacterium (a germ that may cause disease) that can live in the human gut. Some people have it without having any symptoms. In other people it can cause illness ranging from mild diarrhea to severe colitis (infection of the colon).
C. difficile makes toxins that damage the cells that line the colon. The study doctors want to find out how these toxins cause damage to the cells in the colon.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
The purpose of this study is to examine pathogenic mechanisms of Clostridium difficile toxin-mediated intestinal injury and inflammation. Two primary mechanisms will be examined.
- To examine the hypothesis is that microRNA expression profiles are dysregulated by Clostridium difficile toxin exposure and that dysregulation of miRNA expression plays a role in the pathogenesis of C. difficile associated diseases.
- To examine the hypothesis is that the TLR9 receptor mediates key inflammatory events in response to Clostridium difficile toxin exposure.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02215
- Beth Israel Deaconess Medical Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Age greater than 18 yrs and less than 75 years
- Undergoing a clinically indicated colonoscopy
Exclusion Criteria:
- Known, active or recurrent colonic disease including: Clostridium difficile infection, inflammatory bowel disease, microscopic colitis, colon resection for any reason, ischemic colitis, recurrent diverticulitis, colon cancer. Note: Diverticulosis without recurrent diverticulitis, colonic adenomatous or hyperplastic polyps or colonic arteriovenous malformations will not constitute an exclusion
- Diarrhea (an average of more than 3 bowel movements per day at baseline)
- Constipation (an average of fewer than 2 bowel movements per week at baseline).
- Use of systemic steroid or systemic immunosuppressive medication
- Severe renal impairment
- Relative contraindication to colon biopsy including a bleeding diathesis or anti-coagulant use. Note: nonsteroidal antiinflammatory drug or asprin use will not constitute a contra-indication.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Alle fag
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Binding of Toxin A (and B) to TLR9 on the human colorectal epithelial cell surface
Tidsramme: 24 hours
|
As assessed by confocal fluorescence microscopy
|
24 hours
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
effects of a TLR9 antagonist (ODN-TTAGGG) on toxin binding
Tidsramme: 0 hours
|
The change of mean toxin fluorescence on colonocytes will be measured by confocal microscopy using quantitative image analysis software.
|
0 hours
|
|
Binding of Toxin A (and B) to TLR9 on the human colorectal epithelial cell surface
Tidsramme: 0 hours
|
as assessed by confocal fluorescence microscopy
|
0 hours
|
|
Binding of Toxin A (and B) to TLR9 on the human colorectal epithelial cell surface
Tidsramme: 6 hours
|
As assessed by confocal fluorescence microscopy
|
6 hours
|
|
Effects of a TLR9 antagonist (ODN-TTAGGG) on toxin binding
Tidsramme: 6 hours
|
The change of mean toxin fluorescence on colonocytes will be measured by confocal microscopy using quantitative image analysis software.
|
6 hours
|
|
Effects of a TLR9 antagonist (ODN-TTAGGG) on toxin binding
Tidsramme: 24 hours
|
The change of mean toxin fluorescence on colonocytes will be measured by confocal microscopy using quantitative image analysis software.
|
24 hours
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Sykdommer i fordøyelsessystemet
- Patologiske prosesser
- Sykdomsattributter
- Gastrointestinale sykdommer
- Gastroenteritt
- Kolonsykdommer
- Tarmsykdommer
- Bakterielle infeksjoner
- Bakterielle infeksjoner og mykoser
- Gram-positive bakterielle infeksjoner
- Infeksjoner
- Smittsomme sykdommer
- Kolitt
- Clostridium-infeksjoner
Andre studie-ID-numre
- 2013P000174
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .